An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder
Year: 2008
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Institutions: Clinical Research Institute, Pfizer (United States), Wyeth
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2047397795
